Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs

REFERENCES

• Aceves-Avila F. J., Medina F., Fraga A. The antiquity of rheumatoid arthritis: a reappraisal. J. Rheumatol. 2001; 28: 751–757
   Google Scholar
• Bagchi D., Misner B., Bagchi M., Kothari S. C., Downs B. W., Preuss H. G. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Intl. J. Clin. Pharmacol. Res. 2002; 22: 101–110
   PubMedGoogle Scholar
• Bellamy N., Carr A., Dougados M., Shea B., Wells G. Towards a definition of “differences” in osteoarthritis. J. Rheumatol. 2001; 28: 427–430
   PubMed Web of Science ®Google Scholar
• Bongartz T., Sutton A. J., Sweeting M. J., Buchan I., Matteson E. L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275–2285
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Prevalence of disability and associated with health conditions-United States, 1991–1992. MWRW. 1994; 4341: 737–259
   Google Scholar
• Clegg D. O., Reda D. J., Harris C. L., Klein M. A., O'Dell J. R., Hooper M. M., Bradley J. D., Bingham C.O. III, Weisman M. H., Jackson C. G., Lane N. E., Cush J. J., Moreland L. W., Schumacher H. R., Oddis C. V., Wolfe F., Molitor J. A., Yocum D. E., Schnitzer T. J., Furst D. E., Sawitzke A. D., Shi H., Brandt K. D., Moskowitz R. W., Williams H. J. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 2006; 354: 795–808
   PubMed Web of Science ®Google Scholar
• DeParle L. A., Gupta R. C., Canerdy T. D., Goad J. T., D'Altilio M., Bagchi M., Bagchi D. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J. Vet. Pharmacol. Ther. 2005; 28: 385–390
   PubMedGoogle Scholar
• Eaton C. B. Obesity as a risk factor for osteoarthritis: mechanical versus metabolic. Med. Health R I. 2004; 87: 201–204
   PubMedGoogle Scholar
• Gimsa U., Sieper J., Braun J., Mitchison N. A. Type II collagen serology: a guide to clinical responsiveness to oral tolerance?. Rheumatol. Int. 1997; 16: 237–240
   Google Scholar
• Goldring M. B. Osteoarthritis and cartilage: the role of cytokines. Curr. Rheumatol. Rep. 2000; 2: 459–465
   PubMedGoogle Scholar
• Helmick C. G., Lawrence R. C., Pollard R. A., Lloyed E., Hayes S. P. Arthritis and other rheumatoid conditions: who is affected now, will be affected later? National Arthritic Data Workgroup. Arthritic Care Res. 1995; 8: 203–211
   Google Scholar
• Hielm-Bjorkman A. K., Kuusela E., Liman A., Markkola A., Saartr E., Huffuren P., Leppaluoto J., Tulano R. M., Raekallio M. Evaluation of methods for assessment of pain associated with osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 2003; 222: 1552–1558
   PubMed Web of Science ®Google Scholar
• Hougee S., Hartog A., Sanders A., Graus Y. M., Hoijer M. A., Garssen J., Van Den Berg W. B., van Beuningen H. M., Smit H. F. Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice. Eur. J. Pharmacol. 2006; 531: 264–269
   PubMed Web of Science ®Google Scholar
• Matteson E. L. Historical perspective on the classification of vasculitis. Arthritis Care Res. 2000; 13: 122–127
   Google Scholar
• Mowat A. M. The regulation of immune responses to dietary protein antigens. Immunol. Today. 1987; 8: 93–98
   PubMedGoogle Scholar
• Muhlfeld A. S., Floege J. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. Clin. Nephrol. 2005; 63: 221–224
   PubMed Web of Science ®Google Scholar
• Okada Y. Pathoetiology of chronic rheumatoid arthritis-from inflammation to bone destruction. From viewpoint of pathology. Nppon Naika Gakkai Zassi. 2000; 89: 2072–2080
   Google Scholar
• Paroli E., Antonilli L., Biffoni M. A pharmacological approach to glycosaminoglycans. Drugs Exptl. Clin. 1991; 18: 335–343
   Google Scholar
• Peat G., McCarney R., Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann. Rheum. Dis. 2001; 60: 91–97
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference. Medical Economics Company Inc., Montvale52 nd ed. NJUSA 1998
   Google Scholar
• Richardson D. C., Schoenherr W. D., Zicker S. C. Nutritional management of osteoarthritis. Vet. Clin. North Am. Small Anim. Pract. 1997; 27: 883–911
   PubMed Web of Science ®Google Scholar
• Sieper J., Kary S., Sorensen H., Alten R., Eggens U., Huge W., Hiepe F., Kuhne A., Listing J., Ulbrich N., Braun J., Zink A., Mitchison N. A. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheumatol. 1996; 39: 41–51
   PubMedGoogle Scholar
• Trentham D. E. Oral tolerization as a treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 1998; 24: 525–536
   PubMedGoogle Scholar
• Trentham D. E., Dynesius-Trentham R. A., Orav E. J., Bagchi M., Kothari S., Pruess H. G., Bagchi D. Effects of oral administration of type-II collagen on rheumatoid arthritis. Science 1993; 261: 1727–1730
   PubMed Web of Science ®Google Scholar
• Trentham D. E., Halpner A. D., Trentham R. A., Combitche D., Lorenzo C., Sewell K. L., Haflir D. A., Weiner H. L. Use of undenatured type–II collagen in the treatment of rheumatoid arthritis. Clin. Pract. Alter. Med. 2001; 2: 254–259
   Google Scholar
• Weiner H. L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today. 1997; 18: 335–343
   PubMedGoogle Scholar
• Weiner H. L., Friedman A., Miller A., Khoury S. J., Al-Sabbagh A., Santosh L., Sayegh M., Nussenblatt R. B., Trentham D. E., Hafler D. A. Oral tolerance: immunological mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann. Rev. Immunol. 1994; 12: 809–837
   PubMed Web of Science ®Google Scholar